1 osteoporosis treatment in frail populations: a framework for decision- making cathleen...
TRANSCRIPT
1
Osteoporosis Osteoporosis Treatment in Frail Treatment in Frail
Populations: A Populations: A Framework for Framework for
Decision-MakingDecision-MakingCathleen ColCathleen Colón-Emeric, MD, ón-Emeric, MD,
MHScMHSc
Durham VA GRECC andDurham VA GRECC and
Duke University Medical Duke University Medical CenterCenter
2
ObjectivesObjectives
1.1. Evidence for treating frail older Evidence for treating frail older adultsadults
2.2. Why older adults are not getting Why older adults are not getting treatedtreated
3.3. Deciding when and how to treat frail Deciding when and how to treat frail older adults: a framework for older adults: a framework for decision makingdecision making
3
Would you treat Would you treat this patient?this patient?70 yr old male with EF 25%, 70 yr old male with EF 25%,
mild dementia, T score hip -2.6mild dementia, T score hip -2.6 If he was 80 years old?If he was 80 years old? If he had a prior fracture?If he had a prior fracture? If he lived in a nursing home?If he lived in a nursing home? If he was 90 years old?If he was 90 years old? If he had just broken a hip?If he had just broken a hip?
6
Does Fracture Risk Warrant Does Fracture Risk Warrant Treatment?Treatment?
ConditionCondition Fracture RiskFracture RiskLow BMDLow BMD Double for each SD Double for each SD
decreasedecrease
NH ResidenceNH Residence RR up to 10RR up to 10
1/10 white 1/10 white women/yrwomen/yr
Prior FracturePrior Fracture RR 2-3.5 RR 2-3.5
Parkinson’s Parkinson’s DiseaseDisease
RR 2.5RR 2.5
Prostate CancerProstate Cancer RR 2-4RR 2-4
StrokeStroke RR 2.5RR 2.5
7
Bone Density Screening Recommendations for Older
Veterans All women over age 65 VA recommendations:
http://www.hsrd.research.va.gov/publications/esp/Osteoporsis-2007.pdf Osteoporosis Screening Test (OST): [Age(yrs) – Weight
(kg)]*0.2, score <2 are predictive of low BMD Risk factor guided decisions: corticosteroids, prostate
cancer, weight loss, physical inactivity, spinal cord injury
ACP recommendations: Risk factor guided decisions: age, low body weight,
weight loss, physical inactivity, corticosteroids, and previous fragility fracture
8
Is treatment safe and Is treatment safe and effective in older patients?effective in older patients? BisphosphonateBisphosphonate
s, Teriparatide, s, Teriparatide, RaloxifeneRaloxifene No change in No change in
Relative Risk Relative Risk ReductionReduction
Increase in Increase in Absolute Risk Absolute Risk ReductionReduction
Fracture rates by age
0
100
200
300
400
55 yr 65 yr 75 yr 85 yr
Age during follow-up
Fx/1
0,00
0 PY
Alendronate Placebo
Hochberg, JBMR 2005;20:971-6; Boonen, JAGS 2006;54:782-9; Bonnen, JAGS 2004;52:1832-9; Boonen, JAGS 2010
9
Is therapy cost effective in Is therapy cost effective in older patients?older patients? Most models assume Most models assume
5 years BP 5 years BP treatmenttreatment
Estimates vary with Estimates vary with model assumptionsmodel assumptions
BUT, nearly all show BUT, nearly all show increasing cost-increasing cost-effectiveness with effectiveness with advancing ageadvancing age
PTH Cost-PTH Cost-effectiveness stable effectiveness stable with agewith age
-5,000
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
Dollars/ QALY
65 yr 75 yr 85 yr 95 yr
Cost Effectiveness of Universal Screen and Treat
Schousboe, JAGS 2005;53:1607-1704; Lundquivst, Osteoporos Int 2006;17:1459-71
10
Cost Effectiveness with Cost Effectiveness with Lower Life ExpectancyLower Life Expectancy
05,000
10,00015,00020,00025,00030,00035,00040,000
Cost in UK Pounds
High Medium Low
Life Expectancy
Cost Effectiveness of Risedronate in Steroid Induced Osteoporosis
Cost/fx avoided
Cost/QALY
Van Staa, Rheum 2007;46:460-6
11
What is the lag time before What is the lag time before treatment benefit?treatment benefit?
0
5
10
15
20
25
Months
Bisphos PTH Calcitonin Raloxifene Vitamin D
Time to Effectiveness
vertebral non-vert Any
12
Objective 1 SummaryObjective 1 Summary
1.1. Evidence for treating frail older Evidence for treating frail older adultsadults
• Higher risk for fractureHigher risk for fracture• Treatments appear to be equally safe, Treatments appear to be equally safe,
and have greater absolute and have greater absolute fracture reduction fracture reduction
• Cost effectiveness increases with ageCost effectiveness increases with age• Rapid onset of effectivenessRapid onset of effectiveness
2.2. Why are older adults not getting Why are older adults not getting treated?treated?
13
Older Patients are Rarely Older Patients are Rarely Treated for OsteoporosisTreated for Osteoporosis After a hip fractureAfter a hip fracture
Fewer than 10% receive osteoporosis Fewer than 10% receive osteoporosis evaluation evaluation
Fewer than 20% receive osteoporosis Fewer than 20% receive osteoporosis treatmenttreatment
U.S., Canada, Europe, Academic U.S., Canada, Europe, Academic Centers, Community Practices, VA Centers, Community Practices, VA Medical CentersMedical Centers
Wide variation in practice, 0-85%Wide variation in practice, 0-85%Gupta, J Am Med Dir Assoc 2003; Jachna, JAGS, 2005; Colon-Emeric, Osteoporos Int 2006
14
VISN-6 Osteoporosis VISN-6 Osteoporosis Treatment 2006-8Treatment 2006-8
Barnard, Colon-Emeric, 2008
15
Why are Older Patients Not Why are Older Patients Not Treated?Treated?
System Factors
Provider Factors
Patient Factors
Osteoporosis Rx
16
Provider FactorsProvider Factors
KnowledgeKnowledge Clinical Practice GuidelinesClinical Practice Guidelines
Attitudes: Provider SurveyAttitudes: Provider Survey Safe and effective, even in NH residentsSafe and effective, even in NH residents ““Not as important” as competing co-Not as important” as competing co-
morbiditiesmorbidities Not cost effectiveNot cost effective Too many side effectsToo many side effects
Beliefs: “Not my role”Beliefs: “Not my role” Orthopedic surgeons vs. PCPsOrthopedic surgeons vs. PCPs
Colon-Emeric, J Am Med Dir Assoc 2006; Skedros, JBMR 2006; Dreinhoffer, Osteop Int 2005
17
Patient FactorsPatient Factors
Knowledge/Attitudes/BeliefsKnowledge/Attitudes/Beliefs Inadequate informationInadequate information ““Women’s” diseaseWomen’s” disease ““I’ve never broken a bone”I’ve never broken a bone” Concern about side effects especially ONJConcern about side effects especially ONJ
Co-morbiditiesCo-morbidities Nursing Home ResidentsNursing Home Residents Life expectancyLife expectancy
Ribheiro et al. Health Care for Women Int, 2000
18
Common Co-MorbiditiesCommon Co-Morbidities
Parkinson’s DiseaseParkinson’s Disease BPs Increase BMD, may decrease hip fractureBPs Increase BMD, may decrease hip fracture
Renal InsufficiencyRenal Insufficiency BPs have similar efficacy, safe at GFR 30-45 BPs have similar efficacy, safe at GFR 30-45
ml/minml/min DiabetesDiabetes
BPs similar BMD and bone markers changeBPs similar BMD and bone markers change Atrial FibrillationAtrial Fibrillation
Zoledronic acid increased serious events in Zoledronic acid increased serious events in younger women, but no increased risk in older younger women, but no increased risk in older hip fx patientship fx patients
Sato, Neurology 2007;68:911-15; Jamal, JBMR 2007;22:503-8; Keegan, Diabetes Care 2004;27:1547-53; Black, NEJM 2007; Lyles, NEJM 2007
19
Nursing Home ResidentsNursing Home Residents
Alendronate has similar effect on Alendronate has similar effect on BMD and no increased side effects BMD and no increased side effects
Raloxifene has similar effect on Raloxifene has similar effect on markers of bone turnover markers of bone turnover
Zoledronic acid after hip fracture, no Zoledronic acid after hip fracture, no interaction by NH residenceinteraction by NH residence
Greenspan, 2002 Ann Int Med;136:742-6 ; Hansdotter, 2004 JAGS 52:779-83; Lyles, 2007 NEJM 357:1799-809.
20
System FactorsSystem Factors
Multiple “silos” providing Multiple “silos” providing uncoordinated careuncoordinated care
DXA availability for frail patientsDXA availability for frail patients Formularies, Prior AuthorizationsFormularies, Prior Authorizations Availability of Infusion ServicesAvailability of Infusion Services Financial disincentives for Financial disincentives for
community nursing homescommunity nursing homes
21
Objective 2 SummaryObjective 2 Summary
2. Why older adults are not getting 2. Why older adults are not getting treatedtreated
• Patient issuesPatient issues• Provider issuesProvider issues• System issuesSystem issues
3. Deciding when and how to treat 3. Deciding when and how to treat frail older adults: a framework for frail older adults: a framework for decision makingdecision making
22
Is Osteoporosis Treatment Is Osteoporosis Treatment Worthwhile for this Worthwhile for this patient?patient? ConsiderConsider
Life expectancyLife expectancy Risk of fracture in remaining years of Risk of fracture in remaining years of
lifelife Drug EfficacyDrug Efficacy Patient preferencesPatient preferences SafetySafety CostCost
23
Risk of Fracture in Remaining Risk of Fracture in Remaining Life YearsLife Years
Concept from Walther et al. JAMA 2000; Data from U.S. Life Tables and NHANES, calculated by Colon-Emeric, 2008
24
Risk of Fracture in Risk of Fracture in Remaining Life YearsRemaining Life Years
Risk (%) of Fracture in Remaining Life
Remaining Life Years, Women, by health quartile
Remaining Life Years, Men, by health quartile
Sickest Quartile
25
Risk of Fracture in Remaining Risk of Fracture in Remaining Life YearsLife Years
Risk (%) of Fracture in Remaining Life
Remaining Life Years, Women, by health quartile
Remaining Life Years, Men, by health quartile
Healthiest quartile
26
Risk of Fracture in Remaining Risk of Fracture in Remaining Life YearsLife Years
Risk (%) of Fracture in Remaining Life Remaining Life Years, Men, by health quartile
Remaining Life Years, Women, by health quartile
27
Drug Efficacy:Drug Efficacy:NNT with Oral NNT with Oral
BisphosphonateBisphosphonate
Calculated from publicly available data, Colon-Emeric 2008
29
Patient Preferences Patient Preferences and Safetyand Safety
Delivery routeDelivery route FrequencyFrequency Pill sizePill size ComplianceCompliance CostCost
30
Other Conditions that Other Conditions that Influence Choice of TherapyInfluence Choice of Therapy
Gastritis, ulcer disease, dysphagia Gastritis, ulcer disease, dysphagia (oral BPs)(oral BPs)
Prior DVT, recent fracture Prior DVT, recent fracture (raloxifene)(raloxifene)
Hypercalcemia (PTH)Hypercalcemia (PTH) Prior cancer or radiation (PTH)Prior cancer or radiation (PTH) Upcoming major dental procedures Upcoming major dental procedures
(BPs)(BPs) Cognitive, mobility impairment (oral Cognitive, mobility impairment (oral
BPs)BPs) Number of Medications (monthly or Number of Medications (monthly or
yearly)yearly)
31
Practical ConsiderationsPractical Considerations
Addressing Vitamin D deficiencyAddressing Vitamin D deficiency Prevalence 12-70%Prevalence 12-70% Measurement vs. universal repletionMeasurement vs. universal repletion
Need for DXANeed for DXA Often not feasibleOften not feasible Not necessary to start treatment after Not necessary to start treatment after
fracturefracture Only if it will influence my treatment Only if it will influence my treatment
decisionsdecisions
32
Interventions that Improve Interventions that Improve Osteoporosis CareOsteoporosis Care
Hospital patient interview and 6-month phone callHospital patient interview and 6-month phone call Doubled osteoporosis management by PCPDoubled osteoporosis management by PCP11
Faxed clinician remindersFaxed clinician reminders 3-Fold increase in testing and treatment3-Fold increase in testing and treatment33
Guidelines to PCPs and educational materials to Guidelines to PCPs and educational materials to patientspatients Increased BMD testing and discussion with Increased BMD testing and discussion with
MDsMDs44 Audits of performanceAudits of performance
Improved post-fracture osteoporosis testing to Improved post-fracture osteoporosis testing to 80%80%55
1. Gardner MJ et al. J Bone Joint Surg Am. 2005;87:3-7. ; Solomon DH et al. Mayo Clin Proc. 2005;80:194-202; Majumdar SR et al. Ann Intern Med. 2004;141:366-373; Cuddihy MT et al. Osteoporos Int. 2004;15:695-700.
35
Objective 3 SummaryObjective 3 Summary
3. 3. Deciding when and how to treat frail Deciding when and how to treat frail older adultsolder adults Most co-morbidities are not Most co-morbidities are not
contraindications to treatment contraindications to treatment In patients at high risk for fracture with at In patients at high risk for fracture with at
least 2 years of remaining life expectancy, least 2 years of remaining life expectancy, consider pharmacologic therapyconsider pharmacologic therapy
Patient preferences and co-morbidities Patient preferences and co-morbidities influence choiceinfluence choice
Systems Interventions to improve care are Systems Interventions to improve care are neededneeded
36
Would you treat Would you treat this patient?this patient?
RemainiRemaining life ng life (yrs)(yrs)
Major/Major/HipFractHipFracture Risk ure Risk (yrs)(yrs)
NNT 1 NNT 1 additionadditional major al major FxFx
70 yr old70 yr old 6.76.7 11/4.211/4.2 2626
80 yr old80 yr old 3.33.3 12/5.812/5.8 2424
Prior fx or Prior fx or NH NH residentresident
3.33.3 16/7.516/7.5 1818
90 yr old90 yr old 1.51.5 7.7/3.77.7/3.7 ??
37
ConclusionsConclusions
• Older adults could substantially Older adults could substantially benefit from improved benefit from improved osteoporosis careosteoporosis care
• Although there are additional Although there are additional considerations, frail patients with considerations, frail patients with multiple co-morbidities can be multiple co-morbidities can be treated safely treated safely
• Improvements will require Improvements will require collaboration of entire Healthcare collaboration of entire Healthcare community community
38
Contact Information• For questions about this audio conference
please contact Dr. Cathleen Colon-Emeric at [email protected]
• For any questions about the monthly GRECC Audio Conference Series please contact Tim Foley at [email protected] or call (734) 222-4328
• To evaluate this conference for CE credit please obtain a ‘Satellite Registration’ form and a ‘Faculty Evaluation’ form from the Satellite Coordinator at you facility. The forms must be mailed to EES within 2 weeks of the broadcast